

**GRANTED****(IN387503)**

## PDE4 inhibitor compounds for treating antidepressant and anxiolytic related disorders



### NEED

Depression, anxiety, and psychiatric disorders impact millions globally. Current treatments may cause severe side effects, like emesis. But what if there was a treatment that offered better efficacy with fewer side effects?

### TECHNOLOGY OVERVIEW

The invention introduces PDE4 inhibitors, which help treat depression, anxiety, and other psychiatric disorders. These compounds offer improved activity with minimal emetogenic (vomiting-inducing) side effects, enhancing patient compliance and treatment outcomes.

### TECHNOLOGY KEY FEATURES

PDE4 inhibitors, improved efficacy, minimal emetogenic side effects, treatment of depression, anxiety, psychiatric disorders, pharmaceutically acceptable salts and derivatives.

[Read more here](#)

### MARKET ANALYSIS

The global antidepressant market is projected to grow at a CAGR of 3.2% from 2023 to 2033, driven by increasing awareness and demand for safer, more effective treatments. (Source: Market Research Future, 2023)

### Target Industries

1) Pharmaceutical companies developing new psychiatric medications; 2) R&D organizations working on innovative treatments for mental health; 3) Healthcare providers focusing on improving patient adherence to treatment regimens.

### AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,  
BITS Pilani Contact Details: [tec.bits@pilani.bits-pilani.ac.in](mailto:tec.bits@pilani.bits-pilani.ac.in), 91 1596-255913